

Resource Summary Report

Generated by [dkNET](#) on Jul 30, 2026

B6;CB-Gt(pU-21)124Imeg

RRID:IMSR_CARD:490

Type: Organism

Proper Citation

RRID:IMSR_CARD:490

Organism Information

URL: <https://cardmice.com/rbase/strain?strainid=490>

Proper Citation: RRID:IMSR_CARD:490

Description: Mus musculus with name B6;CB-Gt(pU-21)124Imeg from IMSR.

Species: Mus musculus

Notes: gene symbol note: ; mutant stock:

Catalog Number: CARD:490

Database: Center for Animal Resources and Development

Database Abbreviation: CARD

Availability: embryo

Organism Name: B6;CB-Gt(pU-21)124Imeg

Record Creation Time: 20250513T061412+0000

Record Last Update: 20260725T052052+0000

Ratings and Alerts

No rating or validation information has been found for B6;CB-Gt(pU-21)124Imeg.

No alerts have been found for B6;CB-Gt(pU-21)124Imeg.

Data and Source Information

Source: [Integrated Animals](#)

Usage and Citation Metrics

We found 11355 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Xu J, et al. (2026) Etomidate Improves Antitumor Immunity by Suppressing PD-L1 Expression in Hepatocellular Carcinoma Cells. Cellular and molecular gastroenterology and hepatology, 20(2), 101652.

Li H, et al. (2026) Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR. Translational oncology, 63, 102577.

Tan Z, et al. (2026) SIGLEC15 modulates the immunosuppressive microenvironment and suppresses malignant phenotypes in triple-negative breast cancer. Genes & diseases, 13(1), 101799.

Zhang X, et al. (2026) Genetic and Functional Evidence Links Germline Biallelic Inactivating Variants in WWOX to Histological Mixed-Type Thyroid Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(1), e07602.

Yang LY, et al. (2026) Biomimetic universal CAR-mesenchymal stem cell nanohybrids for anti-tumor therapy. Bioactive materials, 57, 267.

Yan Y, et al. (2026) A novel mouse cell line model reveals the tumor intrinsic and immune characteristics of EGFR-mutant lung cancer. Theranostics, 16(2), 1006.

Yang C, et al. (2026) RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement. Oncogene, 45(1), 26.

Shi Y, et al. (2026) piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization. Translational oncology, 63, 102626.

Du H, et al. (2026) Comparative analysis of the efficacy and safety of antibody?drug conjugates, radionuclide?drug conjugates and their combination targeting claudin 18.2 in gastric cancer treatment. Oncology reports, 55(1).

Jiang Y, et al. (2026) Nuclear and cytoplasmic USP30-AS1 coordinately regulate breast cancer progression through HnRNPF/p21 and EZH2/c-Myc/p21 axes. Genes & diseases, 13(2), 101684.

Zeng T, et al. (2025) ANXA1 binds and stabilizes EGFR to promote nasopharyngeal carcinoma radioresistance. Molecular cancer therapeutics.

Vaubel RA, et al. (2025) Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3771.

Lloyd EG, et al. (2025) SMAD4 and KRAS Status Shapes Cancer Cell-Stromal Cross-Talk and Therapeutic Response in Pancreatic Cancer. *Cancer research*, 85(8), 1368.

Esposito M, et al. (2025) Development of retinoid nuclear receptor pathway antagonists through targeting aldehyde dehydrogenase 1A3. *iScience*, 28(11), 113675.

Ortega-Bertran S, et al. (2025) Triple Combination of MEK, BET, and CDK Inhibitors Significantly Reduces Human Malignant Peripheral Nerve Sheath Tumors in Mouse Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(5), 907.

Jiang H, et al. (2025) Inhibition of NAD-GPx4 axis and MEK triggers ferroptosis to suppress pancreatic ductal adenocarcinoma. *Molecular therapy : the journal of the American Society of Gene Therapy*, 33(9), 4618.

Xing YL, et al. (2025) BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma. *Cell reports. Medicine*, 6(6), 102183.

Hu HM, et al. (2025) N^ε-Carboxymethyl-Lysine Drives Centrosome Amplification and Hepatocarcinogenesis via Pathological Dysregulation of the PLK1-CEP20-CCDC116 Axis. *Journal of agricultural and food chemistry*, 73(52), 33215.

Yurkevicz AM, et al. (2025) Tumor-Specific Antigen Delivery for T-cell Therapy via a pH-Sensitive Peptide Conjugate. *Molecular cancer therapeutics*, 24(1), 105.

Dewulf J, et al. (2025) Preclinical synergistic effects when combining a radiolabelled HER2-targeting single domain antibody with PARP inhibitor Olaparib. *Journal of translational medicine*, 24(1), 83.